Drug
Serabelisib clinical trials
Also written TAK-117 and MLN1117.
- studies test it
- 11
- open now
- 2
- in phase 3
- 0
- first study started
- 2011
Keep track of what changes. Save the serabelisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2020 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Millennium Pharmaceuticals, Inc. (6) · Faeth Therapeutics (2) · Avera McKennan Hospital & University Health Center (1) · Joyce O'Shaughnessy (1) · Petra Pharma (1)
Often tested with
Tested in the same studies.
Sapanisertib (7) · Paclitaxel (3) · Docetaxel (1) · Canagliflozin (1)
Studies
Open first, then newest update. How each study uses serabelisib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerRecruitingPhase 1/2Faeth TherapeuticsNCT07558733Written as Serabelisib
- Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingPhase 2Faeth TherapeuticsNCT06463028Written as Serabelisib
- Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsCompletedPhase 1Avera McKennan Hospital & University Health CenterNCT03154294Written as TAK-117
- TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast CancerCompletedPhase 2Joyce O'ShaughnessyNCT03193853Written as Tak-228 & Tak-117
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02725268Written as MLN1117
- MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02724020Written as MLN1117
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknownPhase 1/2Petra PharmaNCT04073680Written as Serabelisib
- A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01899053Written as TAK-117
- Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedPhase 1/2Millennium Pharmaceuticals, Inc.NCT02393209Written as TAK-117
- A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy ParticipantsCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02625259Written as TAK-117
- Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced CancerCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01449370Written as TAK-117
Given in every arm · 2 — serabelisib is usual care beside what is tested
- Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA MutationsTerminatedPhase 1Faeth TherapeuticsNCT05300048Written as Serabelisib
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as MLN1117
Codes
What other systems call serabelisib · ClinicalTrials.gg INT000944
- MeSH (NLM) C000627413serabelisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 43J9Q56T3WSERABELISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27078071serabelisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98844SerabelisibOne source FDA
- DrugBank DB14935One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627413 | serabelisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 43J9Q56T3W | SERABELISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27078071 | serabelisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98844 | Serabelisib | One source FDA |
| DrugBank | DB14935 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.